Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 50-61 http://medscipublisher.com/index.php/cge 58 and optimizing treatment strategies (Morand et al., 2021; Tavares et al., 2024). With the continuous advancement of technology, AI is expected to play a key role in promoting the development of individualized medicine and addressing the current treatment challenges of ovarian cancer. 8.3 Obstacles and solutions for global promotion Although individualized treatment has made progress, there are still significant obstacles to its wide application, especially in areas with insufficient resources. High costs, difficulty in accessing advanced diagnostic technologies and different medical conditions in various regions may limit the use of molecular tests and targeted drugs by many patients worldwide. In addition, the economic burden brought by new therapies in some areas and the lack of insurance coverage make these problems more difficult to solve (Cortez et al., 2017; Chandra et al., 2019). To solve these problems, it is crucial for the international community to join hands and cooperate, share technologies, and develop affordable and easy-to-operate diagnostic platforms. Unifying the standards of clinical treatment, attracting more people to participate in clinical trials, and increasing investment in the training of medical staff can also promote the development of personalized treatment for ovarian cancer worldwide (Cortez et al., 2017; Chandra et al., 2019). Only by ensuring that everyone can equally access innovative treatment methods can the treatment effect of ovarian cancer be improved and the gap in medical levels among different regions be reduced. 9 Concluding Remarks Personalized treatment has greatly revolutionized the treatment model for advanced ovarian cancer, enabling doctors to tailor treatment plans based on each patient's genetic characteristics and actual condition. The continuous advancement of targeted therapies such as PARP inhibitors and anti-angiogenic drugs, as well as immunotherapy methods, has brought hope for extending the time during which patients' conditions do not deteriorate. Some patients with ovarian cancer are even expected to achieve long-term stable control of their conditions. Compared with the uniform standard treatment methods in the past, nowadays, by analyzing the genetic characteristics of tumors and combining biomarkers to plan treatment strategies, doctors can more accurately screen suitable patients, ensuring treatment effects while minimizing drug side effects to the greatest extent. Current clinical treatment recommendations particularly emphasize the importance of multidisciplinary collaboration. Tumor reductive surgery, platinum-based chemotherapy, and targeted therapy or immunotherapy tailored to the individual patient's condition are usually combined. When choosing a specific treatment method, it is necessary to base it on reliable biomarker and genetic testing results. This can not only improve the treatment effect but also avoid unnecessary side effects. However, there are still some key issues that need to be urgently addressed at present, such as how to arrange the sequence and combination of treatments, how to deal with the problem of drug resistance, and how to unify the standards of molecular testing, so as to ensure that all patients can receive personalized treatment fairly. Future research should focus on improving multi-omics techniques, leveraging artificial intelligence to make treatment plans more tailored to the specific circumstances of each patient, and accurately assess the post-treatment outcomes. In addition, it is necessary for all parties to make joint efforts to unify the detection standards of biomarkers, so that more patients can access advanced diagnostic technologies, and at the same time eliminate the differences in the implementation of personalized treatment around the world. The ongoing clinical trials and translational research are crucial for identifying new therapeutic targets, optimizing combined treatment plans, and paying attention to patients' treatment experiences. This is conducive to improving the survival rate and quality of life of patients with advanced ovarian cancer. Acknowledgments I extend my sincere thanks to Dr. Zhou for their feedback on the initial draft of this study .
RkJQdWJsaXNoZXIy MjQ4ODYzNA==